HOME >> BIOLOGY >> NEWS
Charting the future in prostate cancer care: A call to action

LOS ANGELES, Sept. 9 -- This year, an estimated 230,000 men will be diagnosed with prostate cancer in the United States, and 30,000 are expected to die from the disease. Today, about two million men are battling prostate cancer, and over the next decade, about three million more will be compelled to join the war. The need for new therapies is great, and since 1993, The Prostate Cancer Foundation has played a pivotal role in supporting and funding R&D breakthroughs to defeat this disease.

The timing is becoming ever more critical. As the baby boomer men reach the target age for prostate cancer, beginning at age 50, this disease will become the cancer with the greatest increase in incidence, in addition to being the most common non-skin cancer in the U.S. In fact, over the next decade, the number of new prostate cancer cases in the U.S. is expected to increase by 50 percent to more than 300,000 new cases per year. Unfortunately, even today, prostate cancer treatment and research has lagged behind other areas, such as that of breast cancer, where there has been recent progress in integration among specialties and late-stage innovation of new therapeutics.

On September 22, 2004, the Prostate Cancer Foundation (PCF) will release its Report to the Nation on Prostate Cancer, authored by 24 leading prostate cancer experts. A distinguished panel will present the major findings of the Report and its authors' calls to action to address the urgent need to improve the management of prostate cancer and accelerate the development of better treatments and a cure. The PCF will also debut a public service announcement campaign "It's a TEAM Approach: Prostate Cancer Treatment, Education, Awareness and Management". The PSA features golf legend Arnold Palmer, a prostate cancer survivor, who encourages a multi-disciplinary team approach to this deadly disease, which affects one in six men in their lifetime.

Who: Panelists and Special Gues
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
9-Sep-2004


Page: 1 2 3

Related biology news :

1. Lights, Camera ... Reaction: Charting The Biological Effects Of Light InBillionths Of A Second
2. New fruitfly model of diabetes has future implications for pancreatic cell transplantation
3. Sandia experiments may reduce possibility of future water wars
4. Will a reduction in military spending improve our environmental future?
5. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director
6. Engineering endurance: The future of the Olympics?
7. The future of nanotechnology
8. Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
9. Endometriosis: Could angiostatic therapy be the new treatment of the future?
10. Plants for the future: A European vision for plant biotechnology towards 2025
11. Plant pathologists to discuss the future of organic farming

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Charting the future prostate cancer care call action

(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) fertilizers ... high prices in 2008. However, the situation has stabilised ... gaining momentum now. , To date, the world annual ... thousand tonnes. No considerable growth was registered in the ... during 2012-2013, registering 11% growth as against the period ...
(Date:3/27/2015)... Mich. , March 27, 2015  Neogen Corporation ... LLC, has adopted a prearranged trading plan in accordance ... Herbert , Chairman and CEO of Neogen Corporation, is ... of Neogen Corporation common stock. Herbert does ... disclosure was appropriate. The filing is only for a ...
(Date:3/27/2015)... 2015  Peter Walter was chosen as winner of ... work on how proteins are transported between cellular compartments ... that cells use to handle stress tied to the ... of biochemistry at the University of California, San Francisco. ... of human diseases related to defective protein folding and ...
(Date:3/27/2015)... , March 27, 2015 WuXi ... leading open-access R&D capability and technology platform company ... industries, announced today that an Investigational New Drug ... antibody for rheumatoid arthritis has been accepted for ... (CFDA).  In September 2012, MedImmune, ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Neogen CEO adopts 10b5-1 Trading Plan 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3
Cached News: